

TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED
(Formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited)
(Company Registration No.91120000103100784F)
(Incorporated in the People's Republic of China)

**RESPONSE TO SGX-ST'S QUERY ON THE COMPANY'S ANNUAL REPORT FOR THE
FINANCIAL YEAR ENDED 31 DECEMBER 2023**

The board of directors (the "Board") and every individual director of Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited) (the "Company") hereby confirm that they will individually and collectively accept full responsibility for the accuracy of the information given in this announcement, and confirm, having made all reasonable enquiries, that to the best of their knowledge and belief, the facts stated in this announcement are fair and accurate in all material respects as at the date of this announcement, and that there are no material facts the omission of which would make any statement in this announcement misleading.

The Board wishes to provide the following response to the query raised by the Singapore Exchange Securities Trading Limited (the "**SGX-ST**") on 13 May 2024 in relation to the Company's annual report for the financial year ended 31 December 2023 ("**FY2023**") (the "**FY2023 Annual Report**") released via SGXNET on 30 March 2024:-

SGX-ST's Query

At page 50 of the Company's FY2023 annual report, it has stated that the remuneration of its Directors (other than independent directors) and the CEO (or its equivalent rank i.e. the General Manager) for FY2023 is set out in bands of S\$250,000. However, it is noted that the remuneration of Wang Lei and Zhou Hong were disclosed under "S\$250,000 and above, but below S\$750,000" which represents a S\$500,000 band. Please provide the disclosure according to the correct S\$250,000 band(s).

Company's Response

The Company wishes to clarify that the remuneration of Ms. Wang Lei and Mr. Zhou Hong for FY2023 fell within the band of "S\$250,000 and above, but below S\$500,000". Accordingly, the remuneration band for Ms. Wang Lei and Mr. Zhou Hong, as disclosed in the table on page 50 of the FY2023 Annual Report, should be corrected to read as follows (with amendments in **bold, underline and deletions in strikethrough**):

"The remuneration paid to the Directors (other than the Independent Directors) and the Chief Executive Officer (or its equivalent rank, i.e. the General Manager) of the Company for FY2023 is set out below in bands of S\$250,000:

	Salary %	Bonus %	Termination, Retirement and Post- employment benefits %	Other Benefits %	Total %
<i>Below S\$250,000</i>					
<i>Guo Min¹</i>	–	–	–	–	–
<i>Wang Mai²</i>	100	–	–	–	100
<i>Shang Mingjie³</i>	100	–	–	–	100

Zhang Mingrui ⁴	-	-	-	-	-
Mao Weiwen ⁵	-	-	-	-	-
S\$250,000 and above, but below S\$500,000 S\$750,000					
Wang Lei ⁶	100	—	—	—	100
Zhou Hong	100	—	—	—	100

Note(s):

1. No remuneration was paid to Mr. Guo Min for FY2023 by the Company.
2. Mr. Wang Mai ceased to be an Executive Director with effect from 29 March 2023.
3. Mr. Shang Mingjie was appointed as an Executive Director with effect from 21 June 2023.
4. No remuneration was paid to Ms. Zhang Mingrui for FY2023 by the Company.
5. No remuneration was paid to Ms. Mao Weiwen for FY2023 by the Company.
6. Ms. Wang Lei was appointed as an Executive Director with effect from 30 December 2022. She was appointed as the General Manager of the Company on 22 August 2022, and continued as the General Manager of the Company during FY2023."

By Order of the Board

Jiao Yan
Secretary to the Board of Directors
14 May 2024